- Azenta Inc AZTA shares are surging after the company reported better-than-expected Q4 earnings and a buyback of $1.5 billion.
- Q4 revenue was $138 million, flat Y/Y, with organic growth of 2%, beating the consensus of $133.72 million.
- Organic growth was 12% Y/Y, excluding the COVID impact. The estimated COVID impact was approximately $1 million in Q4 FY22 compared to a $12 million contribution in the prior year period.
- Life Sciences Products revenue declined 9% Y/Y mainly due to lower revenue in the consumables and instruments business, partially offset by growth in large-automated stores business.
- Related: Azenta Enhances Position in Cold Chain Solutions With €410M Acquisition.
- The acquisition of Barkey contributed $4 million to revenue.
- Life Sciences Services revenue grew 6% Y/Y, with a 9% growth in sample repository solutions.
- Adjusted EPS of $0.16 came in above $0.12 a year ago, and the consensus of $0.06.
- The company approved a share buyback of $1.5 billion, including an accelerated share repurchase program to repurchase approximately $500 million.
- Guidance: Azenta forecasts Q1 FY23 sales of $175-$190 million and adjusted EPS of $0.08-$0.16, versus the consensus of $163 million and $0.09, respectively.
- For FY23, total revenue is expected to grow approximately 30%.
- Price Action: AZTA shares are up 25.55% at $58.48 on the last check Tuesday.
- Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in